Effect of ruthenium complexes on the activities of succinate dehydrogenase and cytochrome oxidase.
In this article, we report the effects of acute administration of ruthenium complexes, trans-[RuCl(2)(nic)(4)] (nic=3-pyridinecarboxylic acid) 180.7 micromol/kg (complex I), trans-[RuCl(2)(i-nic)(4)] (i-nic=4-pyridinecarboxylic acid) 13.6 micromol/kg (complex II), trans-[RuCl(2)(dinic)(4)] (dinic=3,5-pyridinedicarboxylic acid) 180.7 micromol/kg (complex III) and trans-[RuCl(2)(i-dinic)(4)]Cl (i-dinic=3,4-pyridinedicarboxylic acid) 180.7 micromol/kg (complex IV) on succinate dehydrogenase (SDH) and cytochrome oxidase (COX) activities in brain (hippocampus, striatum and cerebral cortex), heart, skeletal muscle, liver and kidney of rats. Our results showed that complex I inhibited SDH activity in hippocampus, cerebral cortex, heart and liver; and inhibited COX in heart and kidney. Complex II inhibited SDH in heart and hippocampus; COX was inhibited in hippocampus, heart, liver and kidney. SDH activity was inhibited by complex III in heart, muscle, liver and kidney. However, COX activity was increased in hippocampus, striatum, cerebral cortex and kidney. Complex IV inhibited SDH activity in muscle and liver; COX activity was inhibited in kidney and increased in hippocampus, striatum and cerebral cortex. In a general manner, the complexes tested in this work decrease the activities of SDH and COX in heart, skeletal muscle, liver and kidney. In brain, complexes I and II were shown to be inhibitors and complexes III and IV activators of these enzymes. In vitro studies showed that the ruthenium complexes III and IV did not alter COX activity in kidney, but activated the enzyme in hippocampus, striatum and cerebral cortex, suggesting that these complexes present a direct action on COX in brain.
Victor
Eduardo G
EG
Laboratório de Síntese de Complexos Multifuncionais, Universidade do Extremo Sul Catarinense, 88806-000, Criciúma, SC, Brazil.
Zanette
Francine
F
Aguiar
Maira R
MR
Aguiar
Claudia S
CS
Cardoso
Danon C
DC
Cristiano
Maykon P
MP
Streck
Emilio L
EL
Paula
Marcos M S
MM
D000818:Animals; D001921:Brain / Q000201:enzymology; D003576:Electron Transport Complex IV / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D007668:Kidney / Q000201:enzymology; D008099:Liver / Q000201:enzymology; D008297:Male; D018482:Muscle, Skeletal / Q000201:enzymology; D009206:Myocardium / Q000201:enzymology; D009539:Nicotinic Acids / Q000737:chemistry / Q000494:pharmacology; D009942:Organometallic Compounds / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012428:Ruthenium / Q000737:chemistry / Q000494:pharmacology*; D013385:Succinate Dehydrogenase / Q000378:metabolism*
D009539:Nicotinic Acids; D009942:Organometallic Compounds; C403903:dichlorotetrakis(3,5-pyridinedicarboxylic acid)ruthenium(II); C440899:dichlorotetrakis(nicotinic acid)ruthenium(II); D012428:Ruthenium; D013385:Succinate Dehydrogenase; D003576:Electron Transport Complex IV